Caitong International Asset Management’s Autolus Therapeutics AUTL Stock Holding History

Caitong International Asset Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.9K	Sell	16,201 -35,386	-69%	-$55.5K	﹤0.01%	905
2026 Q1	$71.2K	Sell	51,587 -71,692	-58%	-$109K	0.01%	682
2025 Q4	$245K	Buy	123,279 +94,873	+334%	+$146K	0.06%	163
2025 Q3	$46.3K	Buy	+28,406	New	+$55.5K	0.03%	344
2025 Q2	–	Sell	-1,127	Closed	-$1.75K	–	1993
2025 Q1	$1.75K	Sell	1,127 -45	-4%	-$91	﹤0.01%	1404
2024 Q4	$2.75K	Buy	+1,172	New	+$3.96K	﹤0.01%	1128

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Caitong International Asset Management's AUTL Position: Q2 2026 in Review

Caitong International Asset Management reduced its Autolus Therapeutics (AUTL) stake by 69% in Q2 2026, selling an estimated $55.5K and leaving 16,201 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Caitong International Asset Management first reported a position in AUTL in Q4 2024 and has held it in 6 quarters since. The position peaked at $245K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Caitong International Asset Management held 16,201 shares of Autolus Therapeutics worth $25.9K as of Q2 2026.
Caitong International Asset Management sold 35,386 Autolus Therapeutics shares in Q2 2026, an estimated $55.5K.
Autolus Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #905 holding.
Caitong International Asset Management first reported a position in Autolus Therapeutics in Q4 2024 and has held it in 6 quarters since.
Caitong International Asset Management's Autolus Therapeutics position peaked at $245K in Q4 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.